Topic
Intended Use
7 published works
Health Care and Life Sciences
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices
By Dominick DiSabatino, Audrey Mercer, Julian Klein
On June 21, 2023, the U.S. Food and Drug Administration (“FDA”) issued a warning letter to Zyto Technologies, Inc. (“Zyto”), citing Zyto’s promotion of its Hand Cradle Galvanic Skin Response…
Drug & Device Law
FDA Completes “Intended Use” Administrative Marathon
By Bexis
Nearly six years ago, in 2015, the FDA attempted to slip a change to its “intended use” regulations (21 C.F.R. §§201.128, 801.4) – which had not been updated since the…
Drug & Device Law
FDA’s Latest Attempt to Update “Intended Use” Regulations
By Bexis
When we last examined the FDA’s sporadic effort to update the archaic “intended use” regulations (primarily 21 C.F.R. §§201.128 (drugs), 801.4 (devices)), the 2017 bait-and-switch amendment to these regulations had…
Drug & Device Law
FDA Proposes to Delay Off-Label “Intended Use” Rule
Perhaps you have heard that elections have consequences. That is true not only for high-profile issues that hog the headlines on CNN and Fox News, but it is also true…
Drug & Device Law
The Rule of Law is the Best Medicine, Part 2
Last week, we summarized PhRMA’s comments on the FDA’s proposed amendments to regulations regarding “intended uses.” PhRMA showed how the FDA’s insistence that it could read manufacturer’s minds about intended…
Focus on Regulation
KNOWLEDGE ALONE ≠ INTENT: FDA Proposes To Trim One Basis for Determining “Intended Use” of Drugs and Devices
By Susan Lee, Jennifer Agraz Henderson
Last week, the U.S. Food and Drug Administration (FDA) published a proposed rule, 80 Fed. Reg. 57756 (Sept. 25, 2015), that at first blush is devoted to clarifying when a…
Drug & Device Law
Knowledge and Intended Use
By Bexis
Our post last week on the three-ringed FCA circus in U.S. v. King Vassel, got us thinking about another way that misguided plaintiffs try to criminalize off-label use. Deviating from the…